1192711-71-9

Basic information

• Product Name: 2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine;2,4-Dichloro-6-methyl-7H-...;7H-Pyrrolo[2,3-d]pyriMidine,2,4-dichloro-6-Methyl-
• CAS NO: 1192711-71-9
• Molecular Formula: C₇H₅Cl₂N₃
• Molecular Weight: 202.0407
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1192711-71-9.mol

Chemical Properties

• Appearance: /
• Density: 1.572±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.85±0.50(Predicted)
• CAS DataBase Reference: 2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine(1192711-71-9)
• EPA Substance Registry System: 2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine(1192711-71-9)

Safety Data

• Hazardous Substances Data: 1192711-71-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is used as a pharmaceutical intermediate for the synthesis of various medicinal compounds. Its unique structure allows it to serve as a building block in the creation of new drugs, potentially leading to the development of novel therapeutic agents.
Used in Chemical Research:
In the field of chemical research, 2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is utilized for studying its structural and biological activity. Its distinctive chemical properties make it an interesting subject for investigations into new chemical processes and potential applications in various industries.
Used in Drug Development:
2,4-Dichloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is employed in drug development as a key component in the design and synthesis of innovative pharmaceuticals. Its presence in the molecular structure of certain compounds can influence their pharmacological properties, making it a crucial element in the advancement of new treatments for various diseases and conditions.

Upstream product

• 89792-20-1 6-methyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diol 

Downstream Products

• 1116240-25-5 2,4-dichloro-6-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine 
• 1355173-69-1 2-((2-((R)-3-aminopiperidin-1-yl)-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl)methyl)benzonitrile 
• 1355174-84-3 2-((2-chloro-6-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-3-yl)methyl)benzonitrile 

Relevant articles and documents

Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents

Focal adhesion kinase (FAK) is a ubiquitous intracellular non-receptor tyrosine kinase, which is involved in multiple cellular functions, including cell adhesion, migration, invasion, survival, and angiogenesis. In this study, a series of 7H-pyrrolo[2,3-d

Heterocyclic Adenosine Receptor Antagonists

Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of

Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization

We previously reported a highly potent DPP-IV inhibitor 6 with low in vivo efficacy. While trying to maintain consistent in vitro and in vivo biological activity, we initiated a pharmacokinetic property-driven optimization to improve the metabolic stability and permeability of inhibitor 6. A simple scaffold replacement of thienopyrimidine with pyrrolopyrimidine (21a) led to significantly improved metabolic stability (4% vs. 65% remaining). Further modification of the pyrrolopyrimidine scaffold to produce compound 21j resulted in much better oral bioavailability than 6. Importantly, compound 21j exhibits greater in vivo efficacy than does 6 and Alogliptin and is worthy of further development.

INHIBITORS OF PROTEIN KINASES

The present invention is directed to compounds of formula (I)-(II) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.